Clinical trials

The main focus of DERMATACT is to assist clinical trials in the field of dermatology. The index number DTI is advantageously employed by research groups in academia and industry as an additional endpoint. Accordingly, contract research organisations (CROs) profit largely from employing DERMATACT assay technology.

Skin responses may show considerable inter-personal differences. Additional profiling of individuals in the test-cohort prior to starting  the trial can narrow this gap.

Efficacy testing

New substances have to undergo clinical trials. A potential influence on tissue integrity can be tested now on the cellular level.

 

Dermatact is applicable to both topical and systemic treatments;

Formulations can make a difference. Individual tolerability of ingredients is comprised in the DTI readout parameter.

Occupational health

Daily life exposes skin to various challenges.

Many workplaces contain hazardous compounds.

 

Skin contamination may lead to cellular stress or even a compromised barrier function.

Also the public and private space may bear risks for skin irritation: detergents, air pollutants, textiles etc.

DERMATACT can test for individual reaction to environmental factors.

Therapy monitoring

Some diseases are chronic-recurring with symptom-free intervals.

Within a cohort of diagnosed patients, the response to standard treatment may vary.

 

Using DERMATACT, individual kinetics of skin healing can be followed even after disappearance of visible symptoms.

A rise in texture index (DTI) may announce a future reoccurence, thus enabling to counteract early on.

Individuals

Offering next-level sensitivity, DERMATACT opens up chances for preventive medicine. An individual risk can be profiled – inborn or acquired.

If skin cells are stressed, they need additional care for optimum protection.

Newborn risk for AD

The incidence of atopic dermatitis (AD) in newborn > 10%. Children suffer from itch, but cannot tell their parents. About half of the cases could be avoided by intensified skin care.

 

 

DERMATACT helps to decide, whether additional care products should be applied.

Moisture Need

The surface structure of corneocytes strongly correlates to the proteins (NMF), that keep the skin humid – and hence elastic. Effective control is supported by a good monitoring.

 

 

DERMATACT may give advice, whether moisturizing emolllient is recommended or further skin care is superfluous.

Solar Damage

Exposure to ultraviolet light (UV) may harm skin cells. The tolerance level varies individually, also within lighter skin category (skin cancer is not a simple function of UV-lifetime dosage).

 

 

DERMATACT can ascertain the degree of cell damage, that may cause premature aging and even skin cancer.